References
- Papachristos A, Patel J, Vasileiou M, Patrinos GP. Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics. Cancers (Basel). 2023;15(12):3233. Published 2023 Jun 18. doi:10.3390/cancers15123233.
- Patel JN. Application of genotype-guided cancer therapy in solid tumors. Pharmacogenomics. 2014 Jan;15(1):79–93. doi: 10.2217/pgs.13.227. PMID: 24329193.
- Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC MD, Hong DS. Moving Beyond 3+3: The Future of Clinical Trial Design. Am Soc Clin Oncol Educ Book. 2021;41:e133–e144. doi:10.1200/EDBK_319783.
- Shah M, Rahman A, Theoret MR, Pazdur R. The Drug-Dosing Conundrum in Oncology - When Less Is More. N Engl J Med. 2021 Oct 14;385(16):1445–1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9. PMID: 34623789.
- Goldstein, M.J., Peters, M., Weber, B.L. and Davis, C.B. (2021), Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency-Guided First-in-Human Studies. Clin Transl Sci, 14: 536–543.
- Yagishita S, Hamada A. Monoclonal antibody pharmacogenomics in cancer treatment. J Cancer Metastasis Treat 2019;5:75. http://dx.doi.org/10.20517/2394-4722.2019.026.
- Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect. 2021 Apr;9(2):e00757. doi: 10.1002/prp2.757. PMID: 33745217; PMCID: PMC7981594.
- Papakatsika S., Orfanidou M., Rentzeperi E., Emmanouilides C.. Change of dosing paradigm in oncology. Forum of Clinical Oncology. 2024;0(0): -. https://doi.org/10.2478/fco-2023-0022.